These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16900855)

  • 1. Renoprotective effect of renin-angiotensin system block: what has happened?
    Camici M
    Clin Ter; 2006; 157(3):277-82. PubMed ID: 16900855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renin-angiotensin system modulation for treatment and prevention of cardiovascular diseases: toward an optimal therapeutic strategy.
    Giles TD
    Rev Cardiovasc Med; 2007; 8 Suppl 2():S14-21. PubMed ID: 17401312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for combining blockers of the renin-angiotensin system.
    Azizi M; Wuerzner G
    Semin Nephrol; 2007 Sep; 27(5):544-54. PubMed ID: 17868792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic efficacy of renin-angiotensin blockade in patients receiving dialysis.
    Suzuki H
    Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):397-405. PubMed ID: 19491138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Renin-angiotensin system modulation: instructions for use].
    Bellis A; Rozza F; Crispo S; Trimarco B
    G Ital Cardiol (Rome); 2008 Feb; 9(2):79-89. PubMed ID: 18383770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials.
    Fernandez-Juárez G; Barrio V; de Vinuesa SG; Goicoechea M; Praga M; Luño J
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S250-4. PubMed ID: 17130270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual blockade of the renin-angiotensin system for cardiorenal protection: an update.
    Arici M; Erdem Y
    Am J Kidney Dis; 2009 Feb; 53(2):332-45. PubMed ID: 19166800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Weber MA
    Am J Cardiol; 2007 Aug; 100(3A):45J-52J. PubMed ID: 17666198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension.
    Tocci G; Sciarretta S; Facciolo C; Volpe M
    Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):767-76. PubMed ID: 17605654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New therapeutic strategies with combined renin-angiotensin system inhibitors for pediatric nephropathy.
    Zaffanello M; Franchini M; Fanos V
    Pharmacotherapy; 2008 Jan; 28(1):125-30. PubMed ID: 18154482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maximizing inhibition of the renin-angiotensin system with high doses of converting enzyme inhibitors or angiotensin receptor blockers.
    Berl T
    Nephrol Dial Transplant; 2008 Aug; 23(8):2443-7. PubMed ID: 18467376
    [No Abstract]   [Full Text] [Related]  

  • 14. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renin-angiotensin-aldosterone system blockade in diabetes: role of direct renin inhibitors.
    Estacio RO
    Postgrad Med; 2009 May; 121(3):33-44. PubMed ID: 19491538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers.
    Nickenig G; Ostergren J; Struijker-Boudier H
    J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7 Suppl 1():S1-7. PubMed ID: 16969748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease.
    Toto R; Palmer BF
    Am J Nephrol; 2008; 28(3):372-80. PubMed ID: 18073461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A; Teo KK
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the renin-angiotensin-aldosterone system in cardiovascular progenitor cell function.
    Qian C; Schoemaker RG; van Gilst WH; Roks AJ
    Clin Sci (Lond); 2009 Feb; 116(4):301-14. PubMed ID: 19138171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.